Using patients' own blood to reduce transfusions in heart surgery
Autologous Whole Blood Management for Reduction of Blood Product Transfusion in Adult Cardiac Surgery Patients: a Local Feasibility/Pilot Study
This study is testing if using patients' own blood during heart surgery can help them recover better and need less donated blood.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 64 (estimated) |
| Ages | 18 Years to 85 Years |
| Sex | All |
| Sponsor | University of Alberta Academic / other |
| Locations | 1 site (Edmonton, Alberta) |
| Trial ID | NCT05889494 on ClinicalTrials.gov |
What this trial studies
This pilot trial aims to evaluate a protocol for a larger clinical trial that investigates the effectiveness of using autologous whole blood in adult cardiac surgery patients. Participants will be randomly assigned to either receive their own blood or donated blood products during surgery. The study will assess the practicality and efficiency of this approach, focusing on outcomes such as bleeding, the volume of donated blood products used, and postoperative complications. The goal is to determine if using a patient's own blood can lead to better health outcomes and reduced reliance on donated blood.
Who should consider this trial
Good fit: Ideal candidates are adults undergoing cardiac surgery at the Mazankowski Alberta Heart Institute who are at high risk for acquired coagulopathy.
Not a fit: Patients with severe pre-existing conditions such as significant renal impairment, severe anemia, or those undergoing emergency surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the need for donated blood products and associated complications in cardiac surgery patients.
How similar studies have performed: While there is limited large-scale evidence on this specific approach, similar blood conservation methods have shown promise in reducing transfusion-related complications.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (≥18 yr) * Surgical patients at the Mazankowski Alberta Heart Institute * High risk for acquired coagulopathy Exclusion Criteria: * Left ventricular ejection fraction \<20% * Impaired renal function * Preoperative anemia (hematocrit \< 30%) * Abnormal coagulation studies or platelet function * Presence of hemoglobinopathy * Platelet count \< 120 10\*9/L * Non-heparin based CPB anticoagulation * Presence of carotid stenosis (≥70%) * Presence of bacteremia/endocarditis * Age \> 85 yr * Weight \< 55 kg * Hepatic failure/dysfunction * Pregnancy * Chronic lung disease on home O2 * Acute respiratory failure * Acute coronary syndromes * Emergency surgery
Where this trial is running
Edmonton, Alberta
- University of Alberta — Edmonton, Alberta, Canada (Recruiting)
Study contacts
- Principal investigator: Angela R Neufeld, MD — University of Alberta
- Study coordinator: Angela R Neufeld, MD
- Email: angela.neufeld@ualberta.ca
- Phone: (780) 407-8861
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.